Clinical trials: Systemic Lupus Erythematosus (Sle)
Systemic Lupus Erythematosus
Alnuctamab for Refractory SLE (LATTE Study)
This study will assess the safety and preliminary efficacy of the bi-specific TCE, alnuctamab (known as BMS-986349, CC-93269, EM901), targeting BCMA in patients with moderate to severe SLE, refractory to standard-of-care…
- Trial name
- NCT07219563
- Testing
- Alnuctamab
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Interstitial Lung Disease, Connective Tissue Disease
A Clinical Trial for CTD-ILD Treatment
The first objective of this protocol is to assess the tolerability and safety of N-acetylcysteine (NAC) in patients with connective tissue disease related interstitial lung disease (CTD-ILD).
- Trial name
- NCT01424033
- Testing
- N-Acetylcysteine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Michigan
Lupus Nephritis
Serological and Urinary Biomarkers in Latin American Patients With Systemic Lupus Erythematosus: GLADEL 2.0 Cohort
Lupus nephritis (LN) is one of the main manifestationsin SLE patients, having an important impact on morbidity and mortality. Renal biopsy is the "gold standard" for the diagnosis of LN, however, it is an invasive technique, not…
- Trial name
- NCT04534647
- Testing
- different serum and urine biomarkers
- Where
- Argentina
- Volunteers
- 100 people
- Sponsor
- Liga Panamericana de Asociaciones de Reumatologia (PANLAR)
Systemic Lupus Erythematosus, Lupus Nephritis
Serum MPO-DNA Complexes as a Biomarker of Disease Activity in Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by immune system dysregulation and inflammation affecting multiple organs.
- Trial name
- NCT07805863
- Volunteers
- 90 people
- Sponsor
- Assiut University
Nephrotic Syndrome, Systemic Lupus Erythematosus
Drug Therapy in Lupus Nephropathy
Studies have shown that up to 26% of patients with systemic lupus erythematoses nephritis may suffer from membranous lupus nephropathy.
- Trial name
- NCT00001212
- Testing
- prednisone, cyclophosphamide, cyclosporin A
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Systemic Lupus Erthematosus
Ivarmacitinib Versus Glucocorticoids in Mild-to-Moderate Systemic Lupus Erythematosus
This randomized, double-blind, parallel-group, noninferiority clinical trial will evaluate the efficacy and safety of ivarmacitinib compared with oral prednisone in participants with mild-to-moderate active systemic lupus…
- Trial name
- NCT07814664
- Testing
- Ivarmacitinib Sulfate Tablets, Prednisone Acetate Tablets
- Where
- China
- Volunteers
- 294 people
- Sponsor
- Chinese SLE Treatment And Research Group
Systemic Lupus Erythematosus
Observational Multicenter Case-control Study to Assess Nailfold Capillary Abnormalities in Systemic Lupus Erythematosus
The purpose of this study is to investigate the role of nailfold capillaroscopy in the assessment of patients with Systemic Lupus Erythematosus (SLE).
- Trial name
- NCT02801812
- Testing
- nailfold capillaroscopy
- Volunteers
- 364 people
- Sponsor
- ASST Gaetano Pini-CTO
Metabolic Syndrome, Cardiovascular Risk Factors
A Study of the Metabolic Syndrome in Patients With Systemic Lupus Erythematosus
An increased prevalence of the metabolic syndrome has been found in patients with systemic lupus erythematosus in recent years.
- Conditions
- Metabolic Syndrome, Cardiovascular Risk Factors, Systemic Lupus Erythematosus
- Trial name
- NCT00982670
- Where
- Taiwan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Far Eastern Memorial Hospital
Active Systemic Lupus Erythematosus
Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus
The primary objective is to evaluate the efficacy and safety of efavaleukin alfa in subjects with active systemic lupus erythematosus.
- Trial name
- NCT04680637
- Testing
- Efavaleukin Alfa, Standard of Care
- Where
- 150 sites in United States, Austria and 17 more
- Volunteers
- 168 people
- Sponsor
- Amgen
Discoid Lupus Erythematosus, Systemic Lupus Erythematosus
Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)
Evaluate the activity and safety of oral tofacitinib in adult patients with discoid lupus erythematosus with or without concurrent SLE.
- Trial name
- NCT03159936
- Testing
- Tofacitinib citrate
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Tufts Medical Center
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)
The ImmuneNet study is a Phase I/II clinical trial sponsored by Truway Health, Inc. It will test whether gentle, low-frequency electromagnetic resonance (LF-EMR) can influence how immune cells communicate and synchronize with…
- Conditions
- Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases
- Trial name
- QSIT (NCT07221565)
- Testing
- Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Low-Dose Naltrexone (LDN)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Truway Health, Inc.
Systemic Lupus Erythematosus, Sleep Disorders
Aerobic Exercise on Improving Sleep in Systemic Lupus Erythematosus.
The purpose of this study is to determine the effectiveness of exercise training on improving sleep in patients with systemic lupus erythematosus.
- Trial name
- EFEXO (NCT02037971)
- Testing
- Aerobic Exercise, Control Group
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Federal University of São Paulo
Systemic Lupus Erythematosus, Lupus Nephritis
CHT105 for the Treatment of Refractory Lupus Nephritis
Systemic lupus erythematosus (SLE) is the most common systemic autoimmune disease in China. The kidneys are the organ most frequently affected in SLE and a major cause of mortality among SLE patients.
- Trial name
- NCT07517536
- Testing
- anti-CD19/70 CAR T cells (CHT105)
- Where
- China
- Volunteers
- 14 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Systemic Lupus Erythematosus, Systemic Scleroderma Meeting
ROLE of PLATELETS in the PATHOPHYSIOLOGY of SYSTEMIC LUPUS
Blood platelets, well known for their role in hemostasis, are abnormally activated in patients suffering from systemic lupus erythematosus (SLE), but also from other immunomediated diseases (scleroderma, vasculitis, myositis…
- Conditions
- Systemic Lupus Erythematosus, Systemic Scleroderma Meeting, ANCA Vasculitis, Inflammatory Myositis
- Trial name
- PLAQUETTOLUP (NCT06593041)
- Where
- France
- Volunteers
- 450 people
- Sponsor
- University Hospital, Strasbourg, France
Lupus Erythematosus, Systemic
Anti-ficolin-3 Autoantibodies in Lupus Nephritis
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of multiple autoantibodies. Antibodies against Ficolin-3 were previously identified in the sera of some SLE patients, but their…
- Trial name
- ficolupus (NCT02625831)
- Testing
- Biological analysis
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
COVID-19, Systemic Lupus Erythematosus
Prevalence and Seroconversion of COVID-19 in Autoimmune Diseases in Europe
The coronavirus disease 2019 (COVID-19) pandemic is a potentially fatal disease that represents a great global public health concern.
- Conditions
- COVID-19, Systemic Lupus Erythematosus, Sjogren's Syndrome, Axial Spondyloarthritis
- Trial name
- Euro-COVIMID (NCT04397237)
- Where
- France
- Volunteers
- 3,100 people
- Sponsor
- Pitié-Salpêtrière Hospital
Systemic Lupus Erythematosus, Idiopahic Inflammatory Myopathies
A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases
The purpose of this study is to assess the safety and efficacy of CD19 UCAR-T cell therapy in Subjects with autoimmune diseases.
- Conditions
- Systemic Lupus Erythematosus, Idiopahic Inflammatory Myopathies, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Sjögren's Syndrome
- Trial name
- ET-902-AID01 (NCT07212322)
- Testing
- CD19 UCAR-T cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Systemic Lupus Erythematosus, Systemic Sclerosis
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in With Relapse/Refractory Autoimmune Diseases.
- Trial name
- NCT07155369
- Testing
- UCAR-T cells, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 18 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Lupus or SLE, Interstitial Lung Disease
Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease
Recent data indicate that Telitacicept is beneficial for lupus nephritis. Our goal is to determine whether Telitacicept is an effective and safe treatment, compared to standard-of-care Cyclophosphamide, for subclinical and…
- Conditions
- Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus
- Trial name
- NCT07077486
- Testing
- Methylprednisolone (Corticosteroid), Immunosuppressant other than CYC, Telitacicept Freeze-dried powder Injection 80mg
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Tongji Hospital
Systemic Lupus Erythematosus, Arthritic Psoriasis
The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients
The purpose of this study is to investigate the effect of BMS-986165 in combination with an oral contraceptive in healthy female patients.
- Conditions
- Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis, Inflammatory Bowel Diseases
- Trial name
- NCT03262727
- Testing
- BMS-986165, Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.